Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX) traded today at a new 52-week high of $8.41. So far today approximately 301,000 shares have been exchanged, as compared to an average 30-day volume of 1.3 million shares.
Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX) defies analysts with a current price ($8.32) 0.4% above its average consensus price target of $8.29.
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing innovative therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with the lambert-eaton myasthenic syndrome.
In the past 52 weeks, Catalyst Pharmaceuticals Inc. share prices are bracketed by a low of $4.16 and a high of $8.41 and is now at $8.32, 100% above that low price.
Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts
To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected
About IBN (InvestorBrandNetwork)
IBN consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and Code Editorial Syndication to 5,000+ broadcast outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign and the NEW normal.
For more information on IBN, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer